Jon Napitupulu

Pleco Therapeutics, a clinical-stage biopharmaceutical company, has received positive feedback from the FDA regarding its Investigational New Drug (IND)...

Abpro Holdings announced preclinical data for its HER2 x CD3 T-cell engager, ABP-102/CT-P72, will be presented at the American...

Quanta Therapeutics will present data on QTX3544, an oral, G12V-preferring, multi-KRAS inhibitor, at the 2025 AACR Annual Meeting. QTX3544...

Bolt Biotherapeutics will present Phase 1 clinical trial data for BDC-3042, a dectin-2 agonist antibody targeting tumor-associated macrophages (TAMs),...

Polyrizon Ltd. has initiated preclinical studies for intranasal delivery of benzodiazepines (BZDs) using its proprietary Trap and Target™ platform....

Corvus Pharmaceuticals provided a business update and announced its financial results for the fourth quarter and year ending December...

Merit Medical Systems announced positive six and twelve-month results from the randomized arm of its WAVE trial, studying the...

NeuroNOS, a Beyond Air subsidiary, secured $2 million in private equity funding to advance the preclinical development of a...

Alumis and Kaken Pharmaceutical have partnered to develop and commercialize ESK-001, a selective TYK2 inhibitor, for dermatological conditions in...

Spark Biomedical has completed enrollment in its pivotal Phase II clinical trial for a non-invasive neurostimulation treatment for Neonatal...